Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish Sells 22,727 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 22,727 shares of the company’s stock in a transaction on Friday, June 13th. The stock was sold at an average price of $11.07, for a total value of $251,587.89. Following the transaction, the chief operating officer now directly owns 748,918 shares in the company, valued at $8,290,522.26. This represents a 2.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Scott Lish also recently made the following trade(s):

• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The stock was sold at an average price of $13.00, for a total value of $719,875.00.
• On Monday, May 5th, Scott Lish sold 12,000 shares of Alphatec stock. The shares were sold at an average price of $12.12, for a total value of $145,440.00.

Alphatec Stock Down 1.5%

Shares of NASDAQ:ATEC opened at $10.85 on Wednesday. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.14. The stock’s fifty day simple moving average is $11.73 and its 200-day simple moving average is $10.83. The company has a market capitalization of $1.59 billion, a P/E ratio of -9.43 and a beta of 1.10.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative net margin of 25.77% and a negative return on equity of 1,657.19%. The company had revenue of $169.18 million during the quarter, compared to analysts’ expectations of $167.57 million. During the same quarter in the prior year, the company earned ($0.34) earnings per share. The firm’s revenue was up 22.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Institutional Trading of Alphatec

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. Nuveen LLC purchased a new stake in shares of Alphatec in the first quarter valued at $135,874,000. Royal Bank of Canada lifted its position in Alphatec by 171.2% during the fourth quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company’s stock worth $29,240,000 after buying an additional 2,010,806 shares during the period. American Century Companies Inc. lifted its position in Alphatec by 36.5% during the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company’s stock worth $45,800,000 after buying an additional 1,334,780 shares during the period. MetLife Investment Management LLC lifted its position in Alphatec by 1,818.5% during the first quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company’s stock worth $12,309,000 after buying an additional 1,150,669 shares during the period. Finally, Nuveen Asset Management LLC lifted its position in Alphatec by 78.4% during the fourth quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company’s stock worth $23,730,000 after buying an additional 1,136,330 shares during the period. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on ATEC. Piper Sandler reissued an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Lake Street Capital raised Alphatec to a “buy” rating and set a $18.00 target price on the stock in a report on Monday. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a report on Monday, April 14th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Alphatec in a report on Friday, May 2nd. Finally, Wall Street Zen raised Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Alphatec currently has an average rating of “Moderate Buy” and a consensus price target of $17.89.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.